Verrica Pharmaceuticals Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $156.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $79.00K, a 6.76% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $77.00K, a 6.94% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $76.00K, a 22.58% increase year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $74.00K, a 20.43% decline year-over-year.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $296.00K, a 3.90% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $308.00K, a 7.69% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $286.00K, a 8.33% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $264.00K, a 15.79% increase from fiscal 2021.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $156.00K 10-Q · filed 2026-08-06 | $232.00K derived: sum of 3 quarters · filed 2026-08-06 | $306.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $77.00K 10-Q · filed 2026-05-12 | $153.00K derived: sum of 2 quarters · filed 2026-05-12 | $227.00K derived: sum of 3 quarters · filed 2026-05-12 | $301.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $76.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $150.00K derived: sum of 2 quarters · filed 2026-03-11 | $224.00K derived: sum of 3 quarters · filed 2026-08-06 | $296.00K 10-K · filed 2026-03-11 |
| 2025-09-30 | $74.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $148.00K derived: sum of 2 quarters · filed 2026-08-06 | $220.00K 10-Q · filed 2025-11-14 | $282.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $74.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $146.00K 10-Q · filed 2026-08-06 | $208.00K derived: sum of 3 quarters · filed 2026-08-06 | $301.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $72.00K 10-Q · filed 2026-05-12 | $134.00K derived: sum of 2 quarters · filed 2026-05-12 | $227.00K derived: sum of 3 quarters · filed 2026-05-12 | $304.00K derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $62.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $155.00K derived: sum of 2 quarters · filed 2026-03-11 | $232.00K derived: sum of 3 quarters · filed 2026-03-11 | $308.00K 10-K · filed 2026-03-11 |
| 2024-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $170.00K derived: sum of 2 quarters · filed 2025-11-14 | $246.00K 10-Q · filed 2025-11-14 | $312.00K derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $153.00K 10-Q · filed 2025-08-12 | $219.00K derived: sum of 3 quarters · filed 2025-08-12 | $296.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $76.00K 10-Q · filed 2025-05-13 | $142.00K derived: sum of 2 quarters · filed 2025-05-13 | $219.00K derived: sum of 3 quarters · filed 2025-05-13 | $291.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $143.00K derived: sum of 2 quarters · filed 2025-03-11 | $215.00K derived: sum of 3 quarters · filed 2025-03-11 | $286.00K 10-K · filed 2025-03-11 |
| 2023-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $149.00K derived: sum of 2 quarters · filed 2024-11-05 | $220.00K 10-Q · filed 2024-11-05 | $290.00K derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $143.00K 10-Q · filed 2024-08-14 | $213.00K derived: sum of 3 quarters · filed 2024-08-14 | $282.00K derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | $71.00K 10-Q · filed 2024-05-13 | $141.00K derived: sum of 2 quarters · filed 2024-05-13 | $210.00K derived: sum of 3 quarters · filed 2024-05-13 | $275.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $139.00K derived: sum of 2 quarters · filed 2024-02-29 | $204.00K derived: sum of 3 quarters · filed 2024-02-29 | $264.00K 10-K · filed 2024-02-29 |
| 2022-09-30 | $69.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $134.00K derived: sum of 2 quarters · filed 2023-11-09 | $194.00K 10-Q · filed 2023-11-09 | $252.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $65.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $125.00K 10-Q · filed 2023-08-08 | $183.00K derived: sum of 3 quarters · filed 2023-08-08 | $240.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $60.00K 10-Q · filed 2023-05-09 | $118.00K derived: sum of 2 quarters · filed 2023-05-09 | $175.00K derived: sum of 3 quarters · filed 2023-05-09 | $232.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $58.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $115.00K derived: sum of 2 quarters · filed 2023-03-06 | $172.00K derived: sum of 3 quarters · filed 2023-03-06 | $228.00K 10-K · filed 2023-03-06 |
| 2021-09-30 | $57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $114.00K derived: sum of 2 quarters · filed 2022-11-07 | $170.00K 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $113.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $56.00K 10-Q · filed 2022-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |